RNS Reach - non-regulatory announcement
26 September 2024
Graft Polymer (UK) Plc
(the "Company")
Proactive Investors interview with Dennis Purcell
Graft Polymer (UK) PLC (LON: GPL), an innovative biotechnology company focused on co-developing therapeutics for mental health disorders, is pleased to note an interview on Proactive Investors with the Company's new Chairman, Dennis Purcell. Mr Purcell's appointment was announced earlier today.
The interview and accompanying article can be viewed at Proactive Investors: Graft Polymer UK appoints biotechnology industry leader Dennis Purcell as Chairman.
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director. anthonytennyson@graftpolymer.co.uk
Allenby Capital (Broker) +44 (0) 20 3328 5656
Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU markets.
For more information, please visit www.graftpolymer.co.uk.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
